Who Paid My Doc
Jocelyn Ang
Pediatric Infectious Diseases Detroit, MI Medical Doctor
NPI 1366489965 CMS profile 430688
3901 Beaubien, 5Th Floor Carl's Bldg, Detroit, MI 48201
General payments
$31,469
Research payments
$98,325
Ownership & investment interest
$0
Research they led as principal investigator
$172,181
Through program year 2025, Jocelyn Ang of Detroit, MI is reported in the CMS Open Payments database as having received $31,469 across 45 general payments and $98,325 in research payments paid to them. Separately, studies naming them as principal investigator received $172,181 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $17,484 | 19 | |
| 2024 | General | $10,271 | 9 | |
| 2023 | General | $2,635 | 3 | |
| 2022 | General | $209 | 3 | |
| 2022 | Research | $13 | 1 | |
| 2021 | Research | $98,312 | 2 | |
| 2019 | General | $869 | 11 |
Beside peers
- Jocelyn Ang
- Pediatric Infectious Diseases median
- Middle half of Pediatric Infectious Diseases
- National median
In program year 2025, general payments to Jocelyn Ang were reported at $17,484. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.
Show as a table
| Year | Jocelyn Ang | Pediatric Infectious Diseases median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $869 | $175 | $34–$2,175 | $163 |
| 2020 | $0 | $521 | $34–$6,009 | $114 |
| 2021 | $0 | $1,077 | $39–$4,557 | $132 |
| 2022 | $209 | $232 | $53–$6,196 | $149 |
| 2023 | $2,635 | $140 | $52–$4,662 | $160 |
| 2024 | $10,271 | $198 | $52–$3,860 | $164 |
| 2025 | $17,484 | $126 | $41–$2,094 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
48 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Infectious Diseases in Michigan
Michael Watson
Pediatric Infectious Diseases · Ann Arbor, MI
Kengo Inagaki
Pediatric Infectious Diseases · Ann Arbor, MI
John Lipuma
Pediatric Infectious Diseases · Ann Arbor, MI
Kay Leopold
Pediatric Infectious Diseases · Ann Arbor, MI
Basim Asmar
Pediatric Infectious Diseases · Detroit, MI
Nahed Abdel-Haq
Pediatric Infectious Diseases · Detroit, MI
Related records
Pediatric Infectious Diseases in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Infectious Diseases
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.